Literature DB >> 7829630

Clinical review 65. Evaluation and treatment of the patient with a pituitary incidentaloma.

M E Molitch1.   

Abstract

Incidental pituitary adenomas are being found commonly with our improved neuroradiological imaging procedures. Screening for hormone oversecretion by these tumors appears to be warranted. For patients with macroadenomas, patients should also be screened for hypopituitarism. In the absence of visual field abnormalities or hypothalamic/stalk compression, it may be appropriate to observe such patients carefully with repeated CT or MRI scans. A limited amount of data suggests that significant tumor enlargement will occur in less than 15% of patients with microadenomas (7). However, all macroadenomas must start out as microadenomas, so periodic follow-up is indicated to assess this possibility. Macroadenomas, by their very existence at the time of detection, have already indicated a propensity for growth. Over the limited period of follow-up in the two series reported, significant growth occurred in almost one third of patients with macroadenomas (7, 8). Hemorrhage into such tumors is uncommon, but anticoagulation may predispose to this complication. When there is no evidence of visual field deficits, an attempt at medical therapy with a dopamine agonist is reasonable, realizing that only about 10% of such patients will respond with a decrease in tumor size. Surgery is indicated if there is evidence of tumor enlargement, especially when such growth is accompanied by compression of the optic chiasm, cavernous sinus invasion, or the development of pituitary hormone deficiencies.

Entities:  

Mesh:

Year:  1995        PMID: 7829630     DOI: 10.1210/jcem.80.1.7829630

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Retrospective multicentric study of pituitary incidentalomas.

Authors:  Patricia Fainstein Day; Mirtha Guitelman; Rosa Artese; León Fiszledjer; Alberto Chervin; Nicolás Marcelo Vitale; Graciela Stalldecker; Valeria De Miguel; Dora Cornaló; Analía Alfieri; María Susana; Mallea Gil
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 2.  Endocrine incidentalomas--challenges imposed by incidentally discovered lesions.

Authors:  Dimitra A Vassiliadi; Stylianos Tsagarakis
Journal:  Nat Rev Endocrinol       Date:  2011-06-28       Impact factor: 43.330

Review 3.  Pituitary incidentalomas.

Authors:  George A Scangas; Edward R Laws
Journal:  Pituitary       Date:  2014-10       Impact factor: 4.107

4.  Pituitary Adenomas.

Authors:  Grant T. Liu
Journal:  Curr Treat Options Neurol       Date:  2002-07       Impact factor: 3.598

5.  Incidental cranial CT findings in head injury patients in a Nigerian tertiary hospital.

Authors:  Godwin I Ogbole; Amos O Adeleye; Mayowa O Owolabi; Richard B Olatunji; Bolutife P Yusuf
Journal:  J Emerg Trauma Shock       Date:  2015 Apr-Jun

Review 6.  The evaluation and management of subclinical pituitary disease.

Authors:  S G Soule; H S Jacobs
Journal:  Postgrad Med J       Date:  1996-05       Impact factor: 2.401

7.  Hyponatremia and pituitary adenoma: think twice about the etiopathogenesis.

Authors:  A Zogheri; A Di Mambro; M Mannelli; M Serio; G Forti; A Peri
Journal:  J Endocrinol Invest       Date:  2006-09       Impact factor: 4.256

8.  Expression of proliferation markers in human pituitary incidentalomas.

Authors:  Masanori Suzuki; Takeo Minematsu; Kenichi Oyama; Shigeyuki Tahara; Shunsuke Miyai; Naoko Sanno; Robert Yoshiyuki Osamura; Akira Teramoto
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

9.  The association of Cushing's disease and primary empty sella turcica.

Authors:  M P Manavela; C M Goodall; S B Katz; D Moncet; O D Bruno
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

10.  Prevalence of GH and other anterior pituitary hormone deficiencies in adults with nonsecreting pituitary microadenomas and normal serum IGF-1 levels.

Authors:  Kevin C J Yuen; David M Cook; Prem Sahasranam; Pragnesh Patel; David E Ghods; Hrayr K Shahinian; Theodore C Friedman
Journal:  Clin Endocrinol (Oxf)       Date:  2008-01-25       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.